MX343659B - Proteínas de unión receptoras fc. - Google Patents

Proteínas de unión receptoras fc.

Info

Publication number
MX343659B
MX343659B MX2013013832A MX2013013832A MX343659B MX 343659 B MX343659 B MX 343659B MX 2013013832 A MX2013013832 A MX 2013013832A MX 2013013832 A MX2013013832 A MX 2013013832A MX 343659 B MX343659 B MX 343659B
Authority
MX
Mexico
Prior art keywords
chemical
soluble
materials
products
solubility
Prior art date
Application number
MX2013013832A
Other languages
English (en)
Spanish (es)
Other versions
MX2013013832A (es
Inventor
Daniel J Sexton
Christopher Tenhoor
Malini Viswanathan
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of MX2013013832A publication Critical patent/MX2013013832A/es
Publication of MX343659B publication Critical patent/MX343659B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2013013832A 2011-06-02 2012-06-01 Proteínas de unión receptoras fc. MX343659B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492617P 2011-06-02 2011-06-02
US201161498266P 2011-06-17 2011-06-17
PCT/US2012/040409 WO2012167039A1 (en) 2011-06-02 2012-06-01 Fc RECEPTOR BINDING PROTEINS

Publications (2)

Publication Number Publication Date
MX2013013832A MX2013013832A (es) 2014-05-20
MX343659B true MX343659B (es) 2016-11-16

Family

ID=47259886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013832A MX343659B (es) 2011-06-02 2012-06-01 Proteínas de unión receptoras fc.

Country Status (14)

Country Link
US (6) US9359438B2 (cg-RX-API-DMAC7.html)
EP (2) EP2714084B1 (cg-RX-API-DMAC7.html)
JP (3) JP6104897B2 (cg-RX-API-DMAC7.html)
KR (1) KR102014554B1 (cg-RX-API-DMAC7.html)
CN (2) CN105622754B (cg-RX-API-DMAC7.html)
AU (2) AU2012262007B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030352B1 (cg-RX-API-DMAC7.html)
CA (1) CA2837527C (cg-RX-API-DMAC7.html)
ES (1) ES2748583T3 (cg-RX-API-DMAC7.html)
IL (1) IL229618B (cg-RX-API-DMAC7.html)
MX (1) MX343659B (cg-RX-API-DMAC7.html)
PH (1) PH12013502378A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201604493TA (cg-RX-API-DMAC7.html)
WO (1) WO2012167039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
SG10201604493TA (en) 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
CN118667014A (zh) * 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
US10822417B2 (en) * 2016-04-25 2020-11-03 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
EP4282487A3 (en) * 2016-07-29 2024-02-14 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
KR20190089941A (ko) 2016-12-01 2019-07-31 사빅 글로벌 테크놀러지스 비.브이. 하이브리드 복합 뒷문
RU2020100880A (ru) * 2017-06-15 2021-07-15 Юсб Биофарма Срл Способ лечения иммунной тромбоцитопении
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
SG11202005021PA (en) 2017-12-13 2020-07-29 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune
MX2021000788A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor de fc (fcrn).
US20230287107A1 (en) * 2019-07-23 2023-09-14 Shanghaitech University Asic1 channel antagonist antibody
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3875456T3 (de) 1987-11-09 1998-06-10 Becton Dickinson Co Verfahren zur Analyse hämatopoietischer Zellen in einer Probe.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
PT1712623E (pt) 1997-01-21 2011-12-21 Gen Hospital Corp Selecção de proteínas utilizando fusões de arn-proteína
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
DE60333554D1 (de) 2002-03-04 2010-09-09 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2007501847A (ja) * 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
WO2006118772A2 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
WO2007087289A2 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20070181136A1 (en) 2006-02-08 2007-08-09 Gelb Michael L Oral appliance
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
TWI593423B (zh) 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
US8537763B2 (en) 2008-06-30 2013-09-17 Motorola Mobility Llc Frame allocation to support legacy wireless communication protocols on uplink transmission
EP2322610B1 (en) * 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human clcp1 antibody and use thereof
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
SG10201604493TA (en) 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune

Also Published As

Publication number Publication date
CN103619353B (zh) 2016-01-06
JP6334763B6 (ja) 2018-07-11
WO2012167039A1 (en) 2012-12-06
SG10201604493TA (en) 2016-07-28
ES2748583T3 (es) 2020-03-17
AU2012262007B2 (en) 2017-06-22
US20240124593A1 (en) 2024-04-18
CN105622754B (zh) 2019-12-27
JP6334763B2 (ja) 2018-05-30
SG195025A1 (en) 2013-12-30
JP6104897B2 (ja) 2017-04-05
US20160304608A1 (en) 2016-10-20
EP2966089A1 (en) 2016-01-13
US11014988B2 (en) 2021-05-25
EP2714084A1 (en) 2014-04-09
IL229618A0 (en) 2014-01-30
AU2017232160B2 (en) 2019-12-19
CN103619353A (zh) 2014-03-05
JP2017169559A (ja) 2017-09-28
KR20140036267A (ko) 2014-03-25
US9862768B2 (en) 2018-01-09
MX2013013832A (es) 2014-05-20
US20200109199A1 (en) 2020-04-09
US20210309741A1 (en) 2021-10-07
NZ618046A (en) 2016-02-26
JP2014523737A (ja) 2014-09-18
US10479834B2 (en) 2019-11-19
HK1195260A1 (zh) 2014-11-07
AU2017232160A1 (en) 2017-10-12
CA2837527A1 (en) 2012-12-06
CA2837527C (en) 2019-05-28
CN105622754A (zh) 2016-06-01
HK1213905A1 (en) 2016-07-15
IL229618B (en) 2018-10-31
US9359438B2 (en) 2016-06-07
US20180305454A1 (en) 2018-10-25
KR102014554B1 (ko) 2019-08-26
EP2714084B1 (en) 2019-05-22
JP2018121657A (ja) 2018-08-09
BR112013030352A2 (pt) 2017-08-01
US12454575B2 (en) 2025-10-28
US20140308206A1 (en) 2014-10-16
JP6638018B2 (ja) 2020-01-29
EP2966089B1 (en) 2020-03-25
US11739152B2 (en) 2023-08-29
BR112013030352B1 (pt) 2020-05-19
EP2714084A4 (en) 2014-11-19
NZ715057A (en) 2017-09-29
PH12013502378A1 (en) 2014-01-06

Similar Documents

Publication Publication Date Title
MX343659B (es) Proteínas de unión receptoras fc.
EA201400008A1 (ru) Система локальной дезинфекции для крупных водоемов
CL2011003150A1 (es) Sistema de tratamiento de aguas residuales que comprende un reactor biologico con un subsistema de separacion que mantiene un adsorbente en el reactor, un sistema de suspension para tal adsorbente, y un sistema de operacion de membrana corriente abajo del reactor, y proceso para tratar aguas residuales que lo comprende.
CL2014000076A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de la enzima dipeptidilpeptidasa iv (dpp-iv); proceso para prepararlos; sal de los compuestos; compuestos intermediarios; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y su uso para tratar diabetes mellitus tipo ii u obesidad.
BR112012031167A2 (pt) processo para a extração de materiais a partir de material biológico
BR112016006226A2 (pt) soluções líquidas que contêm nanobolha
CL2019000878A1 (es) Una solución termosensible y método para su uso.
CL2015000114A1 (es) Anticuerpo anti-fractalkina (anti-fkn): composición farmacéutica que comprende dicho anticuerpo anti-fkn; ácido nucleico; vector; célula huésped; uso del anticuerpo anti-fkn para tratar colitis ulcerosa, enfermedad de crohn, o artritis reumática
BR112017014195A2 (pt) uso de uma corrente de açúcar na fermentação de etanol para produzir mais produtos
BR112014019872B8 (pt) Método para concentrar celulose nanofibrilar, uso de um aparelho de filtração por pressão, e, produto de celulose de fibrila concentrado
EA201990415A1 (ru) Плавучий модуль для модульных платформ солнечных панелей
BR112016021454A2 (pt) Processo de reciclagem de metal pesado e material útil em tal processo
BR112012028706A2 (pt) método para diminuição do ph de uma solução aquosa com o uso de sulfato de uréia na presença de um inibidor de corrosão
MY155720A (en) Novel preparation of an enteric release system
CL2012003727A1 (es) Uso de acidos debiles oxigenados, minerales, compuestos que los generen, para aumentar la recuperacion de cobre en el proceso de lixiviacion o biolixiviacion; procedimiento de lixiviacion o biolixiviacion de cobre que comprende a dichos acidos; y uso de desechos solidos y liquidos de planyas productoras de acidos debiles.
FI20086012L (fi) Käsittelymenetelmä, laite ja käyttö
BR112018077040A2 (pt) resfriamento de elementos de madeira acetilados
AR109248A1 (es) Procedimiento para la preparación de 4-fenilbutirato y sus usos
BR112018002106A2 (pt) adesivos de selagem a frio baseados em dispersões aquosas de poliuretano
UA108629C2 (uk) Поліпшений спосіб отримання розчинних гранул солей піридиновмісних карбонових кислот
MX345526B (es) Procesamiento de químicos.
MY169134A (en) Concentration of the urea solution in a process for the synthesis of urea
MX366015B (es) Mezcla activadora y catalizador iónico para el tratamiento de agua y sus aplicaciones.
BR112016002808B8 (pt) Método para tratamento de água em um lago flutuante e sistema de lago flutuante artificial
Yuenan et al. New search progress and development trend of seawater desalinization technology

Legal Events

Date Code Title Description
FG Grant or registration